At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 209 enrolled
Drug / intervention
INCB054707 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating INCB054707 and Placebo for Hidradenitis Suppurativa and Acne Inversa. Completed, enrolled 209 participants across 40 sites in 6 countries.
Detailed Summary
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa, Acne Inversa
CountriesCanada, France, Germany, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionDec 2021
Study CompletionAug 2023
TodayJul 2026
First PostedJul 17, 2020
Enrollment StartAug 25, 2020
Primary CompletionDec 15, 2021
Study CompletionAug 16, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.0 years ago
Interventions
INCB054707drug
Oral; Tablet
Placebodrug
Oral; Tablet